Several reports have supported the notion that inhibiting cytokine release and/or interrupting the TLR4/Myd88/NF-κB signaling pathway may be effective in reducing the magnitude of LPS-induced depression-like behavior, but not LPS-induced sickness [42,43,44]. Here, TLR4 is linked to depressive symptom measurement.